



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S) : Bowen, et al.  
SERIAL NO. : 10/502,080  
FILED : 10/8/2004  
FOR : Solenopsin A, B and Analogs as Novel Angiogenesis Inhibitors  
GROUP ART UNIT : 4161  
Examiner : Brian M. Gullledge

---

Mail Stop After Final  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Amendment/Response in Application**

**SIR:**

In the above-referenced patent application, in response to the office action of June 11, 2009, please amend the claims as is provided hereinbelow. Note that originally filed claims 3-4, 6, 9-14 and 16-37 were cancelled *without prejudice* pursuant the Examiner's restriction requirement and Applicant's election of invention. The claims cancelled in the previous office action were also canceled without prejudice in order to advance prosecution of the present application, as is the subject matter which is deleted from the previously pending claims and presented herein.